The FDA has approved Baxter Healthcare's hemophilia B drug for use in patients aged 16 years of age and older in the United States. This approval represents the first new treatment for this ...
The drug is administered subcutaneously ... investigating treatments for people living with hemophilia. In April, the FDA ...
The Food and Drug Administration on Friday approved a new kind of medicine for hemophilia, clearing Pfizer’s Hympavzi for people ... to receive Hympavzi, the FDA said. The drug is taken once ...
“Today’s approval of Hympavzi provides patients with hemophilia a new treatment ... The FDA granted Hympavzi Orphan Drug designation for this application. The FDA granted the approval of Hympavzi to ...
Zacks.com on MSN1mon
Pfizer Secures FDA Approval for Hemophilia Drug HympavziPfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...
Based on these results, the FDA approved this drug for a similar indication last month ... The latest decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback